Find a Product

ILscan Services for Human Interleukins and their Receptors

Discover New Ligands or Anti-Receptor and Anti-Ligand Antibodies

Current cell-based methodologies to characterize biologics targeting interleukins include proliferation or cytokine release assays which require the use of primary cells. These primary cells introduce challenges with their inherent donor-to-donor variability and lack of specificity. To address these challenges, DiscoverX offers services for a growing menu of cell-based assays for interleukins that are highly specific and can be used to screen anti-ligand or anti-receptor antibodies and enable rapid development of drugs targeting immune-system disorders.

Use the ILscan Services During:
•    Early discovery and screening

Advantages of ILscan Services
•    Discover novel new ligands
•    Screen anti-ligand and anti-receptor antibodies for most interleukin assays
•    Determine potencies of novel molecules
•    Identify the best candidates for therapeutic development with an assay that resembles in vivo biology

Request a Quote             View Webinar

Want more information? Send an email with your questions to: PathHunterSupport@discoverx.com
 
Ligand Ligand Synonyms Receptor Dimerization Cell Line Part #

IL-1A

IL1A; IL-1A; IL1; IL1-ALPHA; IL1F1

IL-1R1 / IL-1RAP

93-1032C3

IL-2

IL2; IL-2; TCGF; lymphokine

IL-2RB / IL-2RG

93-0998C3

IL-2RB / IL-2RG / IL-2RA

93-1003C3

IL-3

IL3; IL-3; MCGF; MULTI-CSF

IL-3RA / CD131

93-0969C1

IL-4

IL4; BCGF-1; BCGF1; BSF-1; BSF1; IL-4

IL-4R / IL-2RG

93-0988C3

IL-5

IL5; EDF; IL-5; TRF

IL-5RA / CD131

93-0972C3

IL-6

IL6; BSF2; HGF; HSF; IFNB2; IL-6

IL-6R /IL6ST

93-1045C3

IL-7

IL7; IL-7

IL-7R / IL-2RG

93-0997C13

IL-9

IL9; HP40; IL-9; P40

IL-9R / IL-2RG

93-1036C1

IL-10

IL10; CSIF; GVHDS; IL-10; IL10A; TGIF

IL-10RA / IL-10RB

93-0985C3

IL-11

IL11; AGIF; IL-11

IL-11RA / IL6ST

93-1028C1

IL-12

IL12, p70

IL-12RB1 / IL-12RB2

93-1041C3

IL-13

IL13; IL-13; P600

IL-4R / IL-13RA1

93-1000C3

IL-17A

IL17A; CTLA8; IL-17; IL-17A; IL17

IL-17RA / IL-17RC

93-0999C3

IL-18

IL18; IGIF; IL-18; IL-1g; IL1F4

IL-18R1 / IL-18RAP

93-1044C3

IL-21

IL21; CVID11; IL-21; Za11

IL-21R / IL-2RG

93-1035C3

IL-22

IL22; IL-21; IL-22; IL-D110; IL-TIF; ILTIF; TIFIL-23; TIFa; zcyto18

IL-22RA1 / IL-10RB

93-1026C1

IL-23

IL23A; IL-23; IL-23A; IL23P19; P19; SGRF

IL-23R / IL-12RB1

93-1007C3

IL-24

IL24; C49A; FISP; IL10B; MDA7; MOB5; ST16

IL-20RA / IL-20RB

93-1027C3

IL-26

IL26; AK155; IL-26

IL-20RA / IL-10RB

93-1020C3

IL-29

IFNL1; IL-29; IL29

IFNLR1 / IL-10RB

93-0993C3

IL-31

IL31; IL-31

OSMRb / IL-31RA

93-1002C3

IL-33

IL33; C9orf26; DVS27; IL1F11; NF-HEV; NFEHEV; RP11-575C20.2

IL1RL1 (ST2) / IL-1RAP

93-1067C3

OSM

OSM; MGC20461

OSMRb / IL-6ST

93-1056C3

TSLP

TSLP

IL-7R / CRLF2

93-1019C13

ILE/IC50ELECT : Measure your biologics potency values against custom-selected IL family targets or all available IL family targets

ILELECT : Screen collections or a small number of biologics against one or more custom selected IL family targets

Platform Benefits
 
  • Screening biologics for identification of anti-receptor or anti-ligand antibodies
  • Identify new ligands in your programs
  • Obtain results in 15 days saving months in assay development

Highly Specific Assays for Interleukin Receptors Across Multiple Families


Representative examples of assays for interleukin receptors from 6 different families of interleukins / receptors. Each plot shows a dose response for the relevant ligand(s) in a given assay from the indicated family. Data plotted are mean RLU and standard deviation from at least triplicate wells for each dose. These assays are characterized by robust assay windows and low CVs.

Dimerization of Inflammation Targets IL-23R and IL-12R is Highly Specific


Dimerization of IL-23R and IL-12R is highly specific. A. IL23R and IL12R share a common subunit (IL12RB1). Each receptor binds a heterodimeric ligand, which share the p40 subunit. Both receptors have been linked to Crohn’s disease by GWAS studies. B. Dimerization of IL-12R (IL12RB1/IL12RB2) is stimulated by IL-12, but not by IL-23 or p40 monomer. C. Dimerization of IL-23R (IL23R/ IL12RB1) is stimulated by IL-23 but not by IL-12 or p40 monomer.

Verified with Marketed Therapeutics

A Response of IL23R assay to the therapeutic antibody Ustekinumab or Stelara® (Stelara is a registered trademark of Janssen/Centacor) used to treat inflammatory diseases induced by IL-23 or IL-12. The assay has been tested with two different concentrations of IL-23 agonist, at EC80 and EC50 of the agonist response. B Cell-based assay for detecting stimulation and inhibition of IL-6 signaling through the membrane-bound IL-6R. Assay responds to IL-6 with an EC50 of 1.26ng/ml, while tocilizumab (a therapeutic antibody targeting IL-6R) inhibits IL-6-induced dimerization. C Inhibition of IL-6-dependent proliferation of KPMM2 cells with Tocilizumab. IC50 of 1ug/ml for Tocilizumab obtained with a stimulation dose of 1ng/ml (red arrow) is consistent with the IC50 sub value for tocilizumab in the IL6R dimerization assay (as in figure B) run with the same stimulation condition.  Figure adopted from Mihara et al., (2005) Int. Immunopharmacology 5: 1731-40.

Dimerization Assay Principle


The two target receptors are tagged with ProLink™ (PK) or Enzyme Acceptor (EA). Upon ligand-induced activation, the receptors dimerize forcing the two β-gal components to complement and create an active enzyme. Active β-gal generates a chemiluminescent signal in the presence of substrate